Impact of sustained hypertension on new cardiovascular events in patients with type 2 diabetes: KAMOGAWA‐HBP study. Issue 12 (15th November 2022)

• Record Type: Journal Article
• Authors: Yoshimura, Takashi; Ushigome, Emi; Hata, Shinnosuke; Takegami, Maya; Hasegawa, Goji; Tanaka, Toru; Tsunoda, Sei; Ohnishi, Masayoshi; Yokota, Isao; Ushigome, Hidetaka; Kitagawa, Nobuko; Asano, Mai; Hamaguchi, Masahide; Yamazaki, Masahiro; Fukui, Michiaki
• Is Part Of: Journal of clinical hypertension. Volume 24:Issue 12(2022)
• Page Start: 1561
• Page End: 1567
• Publication Date: 2022-11-15
• Subjects: new cardiovascular events -- sustained hypertension -- type 2 diabetes; Hypertension -- Periodicals; 616.132
• DOI: 10.1111/jch.14596
• Languages: English
• ISSNs: 1524-6175

Abstract

Abstract: We have previously shown that masked hypertension (MH) and sustained hypertension (SH) contribute to the progression of diabetic nephropathy. Although the risk of target organ damage and cardiovascular events in MH and SH is significantly higher than that in normotension and white coat hypertension, the role of MH or SH in cardiovascular events has never been reported in studies specific to diabetic patients. Therefore, in this study, we aimed to determine whether blood pressure control status contributes to the development of new cardiovascular events. A longitudinal study of 1082 patients with type 2 diabetes mellitus and no history of cardiovascular events was conducted. Patients were instructed to have their blood pressure measured three times, every morning and evening, for 14 consecutive days. Hypertension status was classified into four groups based on the systolic blood pressure measurements in the clinic and at home. The primary endpoint was the first cardiovascular event. After a median follow‐up of 7.0 (interquartile range, 4.0–9.0) years, 119 patients developed cardiovascular events. The hazard ratio (95% confidence interval) for the risk of developing cardiovascular events was significantly higher in the SH group than in the controlled blood pressure group (1.63 [1.02–2.59]). SH is a useful predictor of cardiovascular events. Both at home and in the clinic, blood pressure monitoring should be assessed in routine clinical practice to predict future cardiovascular events in patients with type 2 diabetes.